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Abstract 
Serotonin-gated ionotropic 5-HT3 receptors are the major pharmacological targets for antiemetic 
compounds. Furthermore, they have become a focus for the treatment of irritable bowel syndrome (IBS) 
and there is some evidence that pharmacological modulation of 5-HT3 receptors might alleviate symptoms 
of other neurological disorders. Highly selective, high-affinity antagonists, such as granisetron (Kytril®) 
and palonosetron (Aloxi®), belong to a family of drugs (the ‘setrons’) that are well established for clinical 
use. To enable us to better understand the actions of these drugs in vivo, we report the synthesis of 8-
fluoropalonosetron (15) that has a binding affinity (Ki = 0.26 ± 0.05 nM) similar to the parent drug (Ki = 
0.21 ± 0.03 nM). We radiolabeled 15 by nucleophilic 18F-fluorination of an unsymmetrical diaryliodonium 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
87
58
6 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
-2- 
 
palonosetron precursor and achieved the radiosynthesis of 1-(methyl-11C)-N-granisetron ([11C]2) through 
N-alkylation with [11C]CH3I, respectively. Both compounds [
18F]15 (chemical and radiochemical purity 
>95%, specific activity 41 GBq/μmol) and [11C]2 (chemical and radiochemical purity ≥99%, specific 
activity 170 GBq/μmol) were evaluated for their utility as PET probes. Using mouse and rat brain slices, in 
vitro autoradiography with both [18F]15 and [11C]2 revealed a heterogeneous and displaceable binding in 
cortical and hippocampal regions that are known to express 5-HT3 receptors at significant levels. 
Subsequent PET experiments suggested that [18F]15 and [11C]2 are of limited utility for the PET imaging 
of brain 5-HT3 receptors in vivo. 
 
Key Words: 5-HT3 receptor; positron emission tomography; granisetron; palonosetron; antagonist; 
imaging. 
 
Introduction 
Palonosetron (1, Aloxi®, Scheme 2) is a potent second generation 5-HT3 receptor antagonist, and is 
the most recently approved drug for preventing acute (0 - 24 h) and delayed (24 - 120 h) emesis following 
moderate chemotherapy, with improved clinical efficacy when compared to early generation antagonists 
such as granisetron (2, Kytril®, Scheme 1).1 In vitro, palonosetron also has a higher binding affinity for 5-
HT3 receptors (Ki = 40 pM) when compared to other antagonists (e.g. granisetron, Ki = 1.45 nM), and an 
extended in vivo plasma elimination half-life.2-4 The reasons for these properties are not fully understood, 
but proposals have included unique allosteric effects, slow ligand dissociation and receptor 
internalization.5,6 
5-HT3 receptors belong to a family of receptors that also includes the γ-amino butyric acid (GABAA), 
glycine and nicotinic acetylcholine (nACh) receptors. This is one of the largest families of ligand-gated ion 
channels and the receptors are responsible for fast synaptic neurotransmission in the central (CNS) and 
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peripheral nervous systems (PNS). All of the receptors are composed of five subunits that surround a central 
ion-conducting channel that spans the cell-surface membrane. Agonist activation of the receptor opens the 
central pore and allows ions to pass from one side of the membrane to the other, causing either 
depolarization or hyperpolarization. The subunits each contain three distinct structural regions termed the 
extracellular, transmembrane and intracellular domains. The extracellular domain is responsible for binding 
agonists that consequently leads to receptor activation. At the 5-HT3 receptor, antagonistic drugs compete 
with serotonin (5-HT) at this orthosteric binding site and prevent the ion channel from opening. This action 
is responsible for alleviating the symptoms of nausea and vomiting.1 Antiemetic activity is believed to 
involve both peripheral receptors and those in the CNS.7-9 Several studies have also suggested that 5-HT3 
receptors are involved in neurological disorders, such as depression, drug abuse, schizophrenia, 
fibromyalgia, pruritus, bulimia nervosa and pain.1,10-12 
Probes such as radioligands, antibodies and oligonucleotides have been used to map the distribution 
of 5-HT3 receptors. First evidence of 5-HT3 receptor expression in the rat brain came from binding studies 
using the selective 5-HT3 receptor antagonist [
3H]GR65630.13 These and other studies have consistently 
found that the highest levels of 5-HT3 receptors in the CNS are located in the dorsal vagal complex in the 
brainstem, and in forebrain regions such as the hippocampus, amygdala, nucleus accumbens, putamen and 
caudate. The dorsal vagal complex includes the area postrema, nucleus tractus solitarius and the dorsal 
motor nucleus of the vagus nerve, regions that are responsible for the vomiting reflex.8 Electrophysiology 
provides support for a predominantly presynaptic localization of these receptors, although some 
postsynaptic 5-HT3 receptors are also reported.
14-17 Expression in other regions of the brain is usually low 
(see ref 18 for a comprehensive review). In the periphery, 5-HT3 receptors are found in vagal afferent nerve 
fibers from the heart and GI tract which are responsible for the Bezold–Jarisch reflex and initiation of 
vomiting reflex, respectively.19-21 5-HT3 receptors have also been found in ganglia of the myenteric plexus 
and submucosal plexus of the human intestine, consistent with their role in mediating gut contractions.22-24 
Elsewhere, lower densities of 5-HT3 receptor can also be found on immune cells and tissues such as the 
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salivary glands.25,26 Because of their wide tissue distribution, specific PET probes might be valuable for 
elucidating the role of 5-HT3 receptors in associated disorders, although relating symptoms of such complex 
neuropsychiatric disorders to single neurobiological processes studied by PET can be challenging.27 
To this end, the synthesis of several PET ligands that target the 5-HT3 receptor were reported in the 
1990s. For instance, 5-HT3 receptor antagonists [
11C]MDL 72222,28,29 [11C]L-683877,30 [11C]Y-25130,31 
[11C]YM06031 and [11C]KF1764332 have been synthesized through N-alkylation with [11C]CH3I and their 
utility assessed in rodents and monkey. Similarly, the clinically-relevant antagonist 2 was 11C-labeled at the 
bicyclic moiety yielding 9-(methyl-11C)-granisetron33 but to the best of our knowledge neither in vitro nor 
in vivo evaluation of this PET tracer was published. Other groups have radiolabeled the non-selective 5-
HT3 receptor agonist N-methylquipazine (NMQ, 2-(4-methylpiperazin-1-yl)quinoline), or partial agonists 
S21007 and MR18445, and evaluated the resulting tracers [11C]NMQ,34 [11C]S2100735,36 and 
[18F]MR1844537 in rat and monkey. However, all of these 5-HT3 receptor PET probes were unsuitable as 
imaging agents, owing to high non-specific binding28,29,32,34,36,37 or low brain uptake.31 More recently, Zheng 
and colleagues have 11C-labeled a series of benzoxazole partial 5-HT3 receptor agonists
38 but no biological 
study with these PET tracers has been reported to date. While writing this manuscript, Mukherjee and 
colleagues also reported the synthesis of novel 5-HT3 receptor ligand (S)-[
18F]fesetron, but found that the 
very low brain uptake in rats impairs its utility as a PET tracer.39  Consequently, in vivo imaging of 5-HT3 
receptors in the CNS and PNS by PET remains to be accomplished. 
Here, we report the synthesis of 1-(methyl-11C)-N-granisetron ([11C]2) and 18F-labeled 
fluoropalonosetron ([18F]15) and use these to characterize the distribution of 5-HT3 receptors in vitro and 
in vivo in rodents.  
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Results and Discussion 
Synthesis of 5-HT3 Receptor Ligands and Precursors for Radiolabeling 
The precursor 3 used for radiolabeling granisetron and unlabeled reference 2 were synthesized as 
shown in Scheme 1. Amide 3 was obtained in good yield following our previously published protocol40 and 
subsequent selective N1-methylation was achieved by treatment with dimethyl carbonate and potassium 
carbonate in refluxing DMF.41 
 
Scheme 1. Synthesis of non-labeled 5-HT3 receptor ligands granisetron (2), quinoline-4-carboxylate 6, and 
labeling precursor 3. Reagents and conditions: (a) 5, DCC, HOBt, CH2Cl2/DMF, rt, 73%. (b) K2CO3, 
dimethyl carbonate, DMF, reflux, 89%. (c) Ac2O, reflux; NaOH, H2O, reflux. (d) POCl3, reflux, 98%. (e) 
SOCl2, reflux; Et3N, EtOH, rt, 89%. (f) 1-methylpiperazine, 140°C, 69%. 
 
In a separate effort to develop novel 5-HT3 receptor ligands based on NMQ, quinoline carboxylate 6 
was discovered to bind with high affinity (Ki = 1.9 ± 1.0 nM) and compete for the same binding site as 
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[3H]granisetron ([3H]2).42 We therefore decided to use structurally different 6 for blocking studies with the 
PET tracers (vide infra). It was synthesized starting from fluoroisatin 7 according to the route developed by 
Cappelli and colleagues for similar compounds (Scheme 1).43 Briefly, 7 was ring-expanded via known 
Pfitzinger reaction to give oxoquinoline carboxylic acid 8,44 which was in turn chlorinated and esterified to 
yield 2-chloroquinoline carboxylate 9. The piperazine substituent was subsequently introduced via SNAr 
reaction and final quinoline carboxylate 6 was isolated in fairly good yield. 
Palonosetron (1) was synthesized according to the published route,45 with some minor experimental 
modifications (Scheme 2). 
 
Scheme 2. Synthesis of reference compounds palonosetron (1), cold fluoropalonosetron 15, and labeling 
precursors 14a-c. Reagents and conditions: (a) (S)-3-Aminoquinuclidine hydrochloride, EDC, HOBt, 
i-Pr2EtN, DMF, rt, 69%. (b) n-BuLi (2 equiv.), THF, -23°C; DMF, -23°C; HCl, H2O, rt, 74%. (c) H2 (25 
bar), Pd(OH)2/C (20 mol%), HClO4, HOAc, 70°C, 90%, dr 46:54; 4M HCl in dioxane/CH2Cl2; 
recrystallization from i-PrOH/H2O, 27% (S,S)-1·HCl; sat. aq. NaHCO3/EtOAc, 96% (d) NIS, CF3SO3H, rt, 
41%. (e) p-TsOH·H2O, mCPBA; anisole or mesitylene, CH2Cl2/TFE, rt; anion exchange, 23-67%. (f) 
Method A: 14a, CsF, MeCN, 100°C, 14%. Method B: 14c, Cu(OTf)2, KF, 18-crown-6, DMF, 60°C, 13%. 
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Tetrahydronaphthalene carboxylic acid 10 was first coupled with chiral (S)-3-aminoquinuclidine mediated 
by EDC and HOBt in DMF. This procedure afforded amide 11 in much higher yields than the reported 
coupling via acid chloride, presumably due to the low solubility of the used quinuclidine hydrochloride in 
apolar organic solvents. Closure of the third ring to give isoquinolinone 12 was achieved by sequential 
lateral C-8 lithiation, formylation with DMF and intramolecular enamine formation. It is important to 
monitor the latter acid-mediated enamine formation and run it to completion, as too short reaction times 
will produce substantial amounts of cyclic hemiaminal (carbinolamine) which can be separated and 
dehydrated separately. The double bond character of the amide bond (lactam) in 12 imparts aromatic 
character to the ring system and hence the reduction of the enamine double bond requires fairly harsh 
conditions. In the event, high pressure of hydrogen in the presence of a palladium catalyst and strong acidic 
conditions at high temperature45 reduced the double efficiently (90% yield) but with no diastereoselectivity 
(dr 46:54 (S,S)-1:(R,S)-1). In order to improve the diastereoselectivity in favor of the desired (S,S)-1 isomer 
we briefly explored a more recent protocol published in a patent46 (H2 (10 bar), 20 mol% Pd(OH)2/C, 58-
62°C, EtOAc) that reported a higher diastereoselectivity (dr 6:4). However, in our hands, applying this 
procedure resulted in very slow conversion and no diastereoselectivity (dr 1:1). The two diastereomers of 
1 were transformed into hydrochloride salts and separated by recrystallization which yielded pure (S,S)-1 
in moderate yield. 
For the introduction of the 18F-label we envisaged to use nucleophilic substitution of an 
unsymmetrical diaryliodonium salt of 1 with [18F]fluoride.47-52 To this end, we searched for methods to 
iodinate palonosetron (1). Direct iodination of non-activated aromatic rings is far less common than the 
corresponding chlorination or bromination. After exploring the few published protocols, the method 
described by Olah and co-workers, that utilizes in situ generated superelectrophilic iodine(I) 
trifluoromethanesulfonate,53 worked best for us. This gave iodopalonosetron 13 as single regioisomer in 
acceptable yield. For the projected formation of diaryliodonium salts from 13 we initially employed the 
published one-pot procedures developed by Bielawski and Olofsson,54 which was later refined by Zhu et 
-8- 
 
al..55 We thought it more prudent to resort to a stepwise addition, as we found that 13 is readily overoxidized 
by excess oxidant (mCPBA), most probably to the corresponding N-oxide. In the reaction, mCPBA and p-
toluenesulfonic acid were added to 13 and complete conversion to the corresponding bis-tosyloxyiodoaryl 
species S1 (Scheme S1) was closely monitored by TLC, after which the aromatic compound was added to 
produce the para-substituted diaryliodonium salts 14 (for experimental details see Methods). Previous 
model studies indicate that nucleophilic fluorination of unsymmetrical diaryliodonium salts preferentially 
leads to 18F-incorporation at the less electron-rich aromatic ring.47 What is more, the counteranion of the 
diaryliodonium salt was found to significantly influence radiochemical yield (RCY).56,57 Therefore, we 
chose to synthesize anisyl- and mesitylpalonosetron iodonium salts, in order to direct 18F-fluorination 
towards the aromatic ring of palonosetron, and prepared 14a-c with different counteranions. Isolation of 
pure and defined diaryliodonium salts is not trivial as handling of such compounds during workup and 
column chromatography leads to partial counterion exchange that is very difficult to analyze. Therefore, 
we utilized a reversed-phase HPLC ion-exchange protocol57 to ensure generation of defined iodonium salts. 
We used diaryliodonium salts 14 to access the standard reference fluoropalonosetron 15 for 
pharmacological characterization and confirming the identity of radiolabeled product by HPLC. To this 
end, anisylpalonosetron iodonium tosylate 14a was heated in the presence of CsF in MeCN.58 The 
fluorination reaction was very slow and did not go to completion after 51 h at 100°C, yet we were able to 
isolate pure 15 after preparative HPLC in low yield. Analysis of the reaction mixture by HPLC revealed 
that most of the starting diaryliodonium 14a was either fluorinated at the anisole moiety (giving 13) or 
thermally decomposed to palonosetron (product ratio 15/13/1 20:39:41). With the aim of improving this 
product ratio and overall yield of 15 we also explored a copper(II) triflate-catalyzed fluorination reaction 
of 14c with naked fluoride that relies on using the mesitylene-ring as dispensable aryl moiety.59 Although 
we did observe complete disappearance of 14c after 24 h at 60°C and obtained a much improved product 
ratio (15/13/1 60:13:27), isolation of pure 15 from this mixture by preparative HPLC proved difficult due 
to the structural similarity of the components. 
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The binding affinity of 15, in competition with [3H]granisetron ([3H]2), was measured in HEK 293 
cells stably expressing the human 5-HT3A receptor and gave a Ki value of 0.26 ± 0.05 nM (n = 4), making 
15 a promising candidate for PET imaging of 5-HT3 receptors. The parent compound palonosetron (1) 
exhibited a similar binding affinity (Ki = 0.21 ± 0.03 nM, n = 5) in the same assay (Figure S1) and as 
reported elsewhere,2 indicating that addition of a small fluorine atom did not significantly affect its binding 
affinity. 
 
Radiolabeling 
The radiosynthesis of 1-(methyl-11C)-N-granisetron ([11C]2) was achieved in a one-step procedure 
by N-methylation with [11C]CH3I in up to 30% RCY (decay corrected to EOB) (Scheme 3). The crude 
product was purified by semi-preparative HPLC and isolated in ≥99% radiochemical and chemical purity. 
The specific activity was in the range of 170 ± 26 GBq/μmol with a total activity of 3.1 ± 1.0 GBq at the 
end of the synthesis (n = 11). Overall, the radiosynthesis of [11C]2 took approximately 40 min from end of 
bombardment.  For all in vitro and in vivo experiments [11C]2 was formulated in 5% ethanol in PBS buffer. 
The diaryliodonium salts 14a-c were 18F-fluorinated using cesium [18F]fluoride/kryptofix (K222) 
complex in DMF in the presence of TEMPO (Scheme 3). The radiolabeling was performed in a homemade 
semi-automated, shielded hot-cell. Under the same reaction conditions, we found that both iodoanisole 
(14a, 14b) and iodomesitylene (14c) leaving groups were displaced by [18F]fluoride in the presence of 
Cs2CO3 and TEMPO in DMF at 140°C after 12 min. In our study, the anisyl iodonium salts (14a and 14b) 
gave slightly higher RCYs than the mesityl iodonium salt (14c) (RCY 6% vs. 4%). For the anisyl iodonium 
salts, the influence of the counteranion on RCY was not significant (data not shown). Furthermore, presence 
of trace amounts of water in the solvent (DMF), as reported by others,57,60 did not increase RCYs. Finally, 
using diaryliodonium precursor 14a, [18F]fluoropalonosetron ([18F]15) could be synthesized and formulated 
for in vivo applications in approximately 6% RCY (decay corrected to EOB, n > 10) and with specific 
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activities at around 41 GBq/μmol at the end of the synthesis. We think that the rather low specific activity 
is probably due to the low radiolabeling yield. The radiochemical purity of [18F]15 was > 95% as determined 
by HPLC. 
 
Scheme 3. Radiosynthesis of [11C]2 and [18F]15. 
 
When analyzing the [18F]fluoride incorporation efficiency by RP-HPLC the influence of the pH of 
the mobile phase was very noticeable. For instance, in the case of the 18F-fluorination reaction with 
precursor 14b we measured 78% [18F]fluoride incorporation by RP-HPLC when using 0.1% aq. TFA in the 
eluent (pH = 2). Analysis of the same reaction using 10 mM aq. NH4HCO3 buffer in the eluent (pH = 7.7) 
gave a significantly lower [18F]fluoride incorporation value (< 3%). Similar observations were recently 
reported by Ory and colleagues who systematically studied the retention of [18F]fluoride on different RP-
HPLC columns that were eluted with mobile phases of different compositions and pH.61 They observed 
increased [18F]fluoride recovery with increasing pH. We reason that hydrogen fluoride (HF), due to its pKa 
value of 3.19,62 is almost completely dissociated at pH 5 and therefore the more polar [18F]fluoride is not 
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retained on the RP-column. At pH 2, however, about 90% of [18F]fluoride is present as [18F]HF which may 
have stronger interactions with the silica core of RP-HPLC columns. Based on these observations, we would 
recommend to use an eluent with pH > 5 for silica based C18 RP-HPLC columns for both analytical and 
semi-preparative RP-HPLC of 18F-labeled compounds. 
 
In vitro Studies with [11C]granisetron and [18F]fluoropalonosetron 
The stability of [11C]2 was assessed in rodent and human plasma over a period of 20 min during 
which no radioactive degradation products were detected (Figure S2). We determined a logD value of 0.43 
± 0.05 (n = 5) at physiological pH (7.4) for [11C]2 and of 0.93 ± 013 (n = 3) for [18F]15. Both PET tracers 
have a basic tertiary amine in their bicyclic moiety and we believe the rather low logD values are likely to 
be due to protonation at physiological pH (calculated pKa values for tertiary amines: 9.3 for 2 and 8.7 for 
15). The calculated lipophilicity (clogP) of the neutral species was 1.7 and 2.4, respectively. 
Radiotracer binding was evaluated by in vitro autoradiography using mouse and rat brain slices as 
shown in Figure 1. Binding of [11C]2 was highest at hippocampus, cortical regions and septal area in both 
mouse and rat which is consistent with previous studies using other 11C-labeled 5-HT3 receptor 
ligands.28,32,36 Binding of [11C]2 to these brain regions was specific as co-incubation with cold competitive 
ligands palonosetron (1, Ki = 0.21 ± 0.03 nM) or quinoline-4-carboxylate 6 (Ki = 1.9 ± 1.0 nM) completely 
diminished the radioactive signal (Figure 1A).  
The binding of [18F]15 to mouse brain sections resulted in a heterogeneous radioactivity pattern with 
signals corresponding to hippocampal and cortical regions, and septal area. Blocking experiments using 
mouse brain slices that were co-incubated with [18F]15 and excess 5-HT3 receptor competitive antagonists 
palonosetron (1) or quinoline-4-carboxylate 6 resulted in complete loss of all these signals (Figure 1B, top 
panels). In rat brain sections incubated with [18F]15, high signal intensity was observed in hippocampal 
regions, which was almost completely abolished by blocking conditions with cold 1 or 6 (Figure 1B, bottom 
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panels) indicating specific binding. This is in line with recent findings where ex vivo microPET images of 
whole rat brain also showed strong hippocampal staining with the palonosetron congener (S)-
[18F]fesetron.39 Specific binding to hippocampus was also observed with high affinity 5-HT3 antagonist 
[3H]GR65630 (Bmax 4.9 ± 0.6 and 1.3 ± 0.3 fmol/mg protein for rat and mouse, respectively).
63 
 
 
Figure 1. Representative autoradiography images of coronal mouse or rat brain sections after incubation 
with (A) [11C]granisetron ([11C]2, 0.6 nM) or (B) [18F]fluoropalonosetron ([18F]15, 0.4 nM) under baseline 
(vehicle) or blocking conditions (co-incubation with palonosetron (1, 1 μM) or quinoline-4-carboxylate 6 
(1 μM)). Autoradiograms are superimposed onto morphological hematoxylin-eosin (HE)-stained slices with 
a color scale for low (blue) to high (red) binding. Identification of specific brain regions was based on HE 
staining and according to the anatomical atlas.64 Scale bars: 2 mm. 
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We attribute the different radioactive labeling patterns of [11C]2 and [18F]15 to the difference of 
mouse and rat brain sections, as indicated by hematoxylin-eosin (HE) staining, as well as their difference 
in chemical structures and specific radioactivities (137-189 GBq/μmol and 41 GBq/μmol, respectively). 
The specific labeling of distinct rodent brain-regions (e.g. hippocampus, cortical regions, septal area) 
encouraged us to evaluate both [11C]2 and [18F]15 as PET tracers in in vivo experiments. 
 
In vivo Studies using [11C]granisetron and [18F]fluoropalonosetron 
In vivo brain-PET scans were performed in rats to study the uptake of [11C]2 and [18F]15 under 
baseline and blocking conditions with palonosetron (1). For both tracers, we found very low and 
homogeneous radiotracer accumulation in the brain (Figure 2A). Further, from these PET scans, we 
calculated the time-activity curves (TACs, Figure 2B) for the brain regions that have been previously 
identified to contain 5-HT3 receptors.
13 Specifically, this earlier study used high-affinity antagonist 
[3H]GR65630 on rat brain homogenates which gave the highest specific binding in the entorhinal cortex 
and area postrema, the latter of which is known to control vomiting. In the MRI-template implemented in 
our biomedical imaging software, the area postrema it is part of the medulla oblongata. No specific binding 
of either [11C]2 or [18F]15 to the aforementioned brain region was detected (Figure 2B). Furthermore, while 
the most intense signal was observed in the pituitary gland, uptake of [11C]2 and [18F]15 was not blocked 
by 1 and indicates that the signal was non-specific. In line with our findings, low brain uptake and strong 
non-specific accumulation of activity in pituitary gland was reported in a recent SPECT imaging study of 
the serotoninergic system in rat (targeting 5-HT1A, 5-HT2A and 5-HT4 receptors, and serotonin transporter 
SERT).65 The absence of specific binding of our 5-HT3 receptor radioligands might be due to the low 
receptor number (Bmax), which was reported to be 1-11 fmol/mg protein in rat and mouse brain when using 
high-affinity 5-HT3 receptor antagonist [
3H]GR65630.63,66 Such low Bmax values make brain 5-HT3 
receptors a highly challenging target for PET imaging. Furthermore, the partition coefficients (logD) of 
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both [11C]2 and [18F]15 are lower than the optimal average lipophilicity value of 2.1 for brain penetrating 
compounds.67 
 
 
Figure 2. (A) PET brain images of Wistar rats using [11C]granisetron ([11C]2, top panels) or 
[18F]fluoropalonosetron ([18F]15, bottom panels) under baseline or blocking conditions (100 μg/kg 1). 
Images are averaged 0-60 min post-radiotracer injection and superimposed on an MRI template, showing 
axial, sagittal and coronal sections (from left to right). SUVmax = 1.5 (PET/CT images) or 0.8 (PET/MRI 
A 
B 
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images). (B) TACs of selected rat brain regions obtained with [11C]2 (top graphs) or [18F]15 (bottom graphs) 
under baseline or blocking conditions. TACs were generated from the same rats as shown in (A). 
 
5-HT3 receptors are not only expressed in the CNS but also in the periphery, most prominently on 
enterochromaffin cells of the GI tract. Body-PET scans of rats using either [11C]2 or [18F]15 revealed 
significant uptake in liver and intestines for both tracers (Figure 3). At late time points, uptake in stomach 
wall was also observed, in particular for [18F]15. Furthermore, we found marked accumulation of [18F]15 
in lungs within the first few minutes after injection. This is similar to other reports where an accumulation 
of PET signal in this organ was detected with 11C-labeled 5-HT3 receptor antagonists [
11C]MDL 72222,28 
[11C]Y-25130,31 [11C]YM06031 and [11C]KF1764332 in rodents. 
 
Figure 3. Coronal PET images of [11C]granisetron ([11C]2, top panels) or [18F]fluoropalonosetron ([18F]15, 
bottom panels) in the lung-liver-intestine region in rat. Time series images averaged over the indicated time 
(in min) post-injection (p.i.). Labels: Lu, lung; Li, liver; St, stomach; Int, intestine. 
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Conclusions 
We have successfully synthesized and radiolabeled the clinically-relevant 5-HT3 receptor antagonists 
granisetron (2) and palonosetron (1). In vitro autoradiography using 1-(methyl-11C)-N-granisetron ([11C]2) 
and [18F]fluoropalonosetron ([18F]15) showed specific labeling in rodent brain slices that were consistent 
with a previous study that used tritiated 5-HT3 receptor antagonist  [
3H]GR65630.13 We found that in vivo 
PET studies in rats gave low and homogenous radiotracer signals of [11C]2 and [18F]15 in brain. We 
speculate that this might be due to 1) the low expression of 5-HT3 receptors in brain (Bmax 1-11 fmol/mg 
protein) and 2) the basic tertiary amino groups of [11C]2 and [18F]15 that in turn leads to 3) low logD7.4 
values for both tracers which is at the lower end of the optimal range (0-3) for passing through the blood-
brain barrier. Although 1 and 2 are very efficient drugs, we conclude that [11C]2 and [18F]15 are not suitable 
radioligands for in vivo PET imaging of 5-HT3 receptors in rodents, and in general, developing specific, 
high-brain uptake 5-HT3 receptor PET tracers remains a challenge. 
 
Methods 
General Chemistry. All reagents and solvents were purchased from Sigma-Aldrich Chemie GmbH 
(Germany), Merck (Germany), Acros (Belgium), ABCR GmbH (Germany) or Fluka (Switzerland). All 
chemicals were used as supplied without further purification, except mCPBA which was dried at high 
vacuum for at least 1 h before use. Anhydrous solvents were obtained by filtration through dry alumina 
columns under argon pressure. Synthesized compounds were >95% in purity determined by analytical 
HPLC method on an Agilent HPLC system. Reactions were monitored by TLC on 0.2 mm ALUGRAM 
Xtra SIL G/UV or POLYRAM Alox N/UV plates (Machery-Nagel). Flash column chromatography was 
carried out using Fluka analytical 60752 silica gel (pore size 60 Å, 40-63 μm particle size) or CAMAG 
507-C neutral aluminum oxide (pore size 60 Å, 40-160 μm particle size).  Infrared (IR) spectra were 
recorded on a Jasco FT-IR-460 Plus. NMR spectra were recorded on a Bruker Avance 300 (1H at 300 MHz, 
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13C at 75 MHz) and Avance II 400 (1H at 400 MHz, 13C at 100 MHz, 19F at 376 MHz). Chemical shifts (δ) 
are reported in ppm referenced to the residual solvent peak. Multiplicities: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad peak. Coupling constants (J) are reported in Hz. High 
resolution mass spectrometry (HRMS) was performed on a Thermo Scientific LTQ Orbitrap XL with a 
Nanospray Ionsource. For purification of radiolabeled product, a semi-preparative Merck-Hitachi L2130 
HPLC system equipped with a radiation detector VRM 202 (Veenstra Instrument, Joure, Netherlands) was 
used with a Waters Symmetry C8 Prep Column (50 x 7.8 mm, 100 Å, 5 µm) and a gradient method: 10 mM 
ammonium bicarbonate buffer (solvent A) and CH3CN (solvent B) 0.0-1.0 min 5% B; 1.0-12.0 min, 5-50% 
B; 13.0-20.0 min, 50% B; 20.0-20.1 min, 50-5% B; 20.1-40.0 min, 5% B at a flow rate of 4 mL/min. For 
product analysis, an analytical Agilent 1100 series HPLC system, equipped with UV multi-wavelength 
detector and a GabiStar radiodetector (Raytest) was used with an ACE C18-AR column (50 x 4.6 mm, 3 
µm) with the following conditions: 0.1% TFA in H2O (solvent A) or 10 mM ammonium bicarbonate buffer 
(solvent A), CH3CN (solvent B); 0.0-8.0 min, 5-50% B; 8.0-9.0 min, 50% B; 9.0-9.1 min, 50-5% B; 9.1-
12.0 min, 5% B at a flow rate of 1 mL/min. 
For the preparation of reference compound 2 and blocker compound 6 see the Supporting 
Information. Labeling precursor 3 was synthesized as published elsewhere.40 
N-((1R,3S,4R)-Quinuclidin-3-yl)-5,6,7,8-tetrahydronaphthalene-1-carboxamide (11). We have 
modified the previously reported synthesis45 of this compound. To a suspension of 5,6,7,8-
tetrahydronaphthalene-1-carboxylic acid (10, 3.98 g, 22.6 mmol), (S)-3-aminoquinuclidine dihydrochloride 
(3.00 g, 15 mmol) and HOBt monohydrate (3.46 g, 22.6 mmol) in 35 mL DMF, was added DIPEA (10.5 
mL, 60 mmol) and EDC (5 mL, 28.7 mmol). The reaction mixture was stirred at rt for 27 h and the reaction 
quenched by the addition of 100 mL 5M NaOH solution. The water phase was extracted EtOAc (3 x 150 
mL), the combined organic layers were washed with 350 mL of 2M NaOH, dried over Na2SO4, filtered and 
concentrated under reduced pressure to afford a yellow oil. EtOAc (70 mL) was added and the organic 
phase was washed again with 2M NaOH (2 x 70 mL), concentrated and the resulting residue co-evaporated 
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with CH2Cl2 (2 x 20 mL), giving an oily foamy solid (5.33 g). The crude product was purified by flash 
chromatography on silica gel, using CH2Cl2/MeOH /Et3N 9:1:0.1, to afford a white foamy solid (3.64 g). 
In order to remove Et3N-contaminations, the compound obtained after flash chromatography was 
partitioned between 100 mL CH2Cl2 and 100 mL sat. aq. NaHCO3 solution. The water phase was extracted 
with CH2Cl2 (2 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated to yield 
11 as a white foamy solid (2.95 g, 69%). 1H NMR (300 MHz, DMSO-d6) δ 8.26 (d, J = 6.9, 1H), 7.17 – 
7.01 (m, 3H), 3.98 – 3.81 (m, 1H), 3.08 (ddd, J = 13.4, 9.7, 2.0, 1H), 2.86 – 2.63 (m, 8H), 2.57 (dd, J = 
14.2, 5.5, 1H), 1.86 (dd, J = 6.1, 3.0, 1H), 1.79 – 1.66 (m, 5H), 1.63 – 1.50 (m, 2H), 1.36 – 1.27 (m, 1H). 
HRMS (ESI+) calcd for C18H25N2O [M+H]
+ 285.1960, found 285.1963. 
2-((1R,3S,4R)-Quinuclidin-3-yl)-2,4,5,6-tetrahydro-1H-benzo[de]isoquinolin-1-one (12). This 
was synthesized according to the original procedure,45 with minor experimental modifications. The reaction 
was run in dry glassware under an atmosphere of argon. To a suspension of amide 11 (3.00 g, 10.55 mmol) 
in 33 mL anhydrous THF at -23 °C (internal temperature), a solution of n-BuLi in hexane 2.5M (10.6 mL, 
26.5 mmol) was added slowly in portions, over a time period of 1.5 h. The temperature was maintained 
between -14 °C and -23 °C during the addition. DMF (1.7 mL, 22.58 mmol) was then added in portions 
over a time period of 2 h. 9 mL 6M aq. HCl was added slowly and the resulting mixture was stirred 
vigorously for 15 min. The two-phase system was concentrated in vacuo to remove most of the THF and 
hexane. After addition of 40 mL 5M NaOH, the water phase was extracted with EtOAc (3 x 120 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford a yellow 
sticky solid (3.13 g). The crude product was purified by flash chromatography on silica gel (CH2Cl2/ 
MeOH/Et3N 9:1:0.1) to give 12 as an off white solid (2.30 g, 74%). IR (neat): 2930, 2868, 1651, 1614, 
1594, 1454, 1321, 1262, 1173, 1055, 978, 822, 766 cm-1. 1H NMR (300 MHz, DMSO-d6) δ 8.05 (dd, J = 
7.9, 1.1, 1H), 7.48 (dd, J = 7.2, 0.9, 1H), 7.44 (s, 1H), 7.39 (m, 1H), 5.01 – 4.92 (pseudo t, 1H), 3.24 (dd, J 
= 10.4, 1.7, 1H), 3.15 – 3.02 (m, 2H), 2.93 (t, J = 6.0, 2H), 2.85 – 2.70 (m, 5H), 1.95 – 1.82 (m, 3H), 1.78 
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– 1.57 (m, 3H), 1.46 – 1.33 (m, 1H). HRMS (ESI+) calcd for C19H23N2O [M+H]
+ 295.1805, found 
295.1796. 
(S)-2-((1R,3S,4R)-Quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one 
hydrochloride (palonosetron hydrochloride, 1·HCl). This was synthesized according to the original 
procedure,45 with some experimental modifications. The reaction was performed in a batch autoclave with 
a vacuum trap inserted as reaction vessel. To a solution of 12 (2.03 g, 6.9 mmol) in 30 mL glacial acetic 
acid, was added HClO4 70% (0.5 mL), Pd(OH)2/C 20% (40% wet, 838 mg, 0.71 mmol, 11 n/n%) and the 
autoclave was closed. After flushing the batch hydrogenator three to five times with approximately 10 bar 
H2, hydrogen pressure was built up to 25 bar and the reaction mixture was stirred at 70 °C for 24 h. The 
instrument was allowed to cool down to rt and the pressure released. The reaction mixture was filtered 
through a plug of celite (pre-washed with MeOH and acetone) and the filter cake washed with MeOH. The 
solvents were removed under reduced pressure and the resulting mixture was partitioned between 10 mL 
CH2Cl2 and 80 mL 5M NaOH. The water phase was extracted with CH2Cl2 (1 x 50 mL and 2 x 20 mL), the 
combined organic layers dried over Na2SO4, filtered and concentrated to afford the crude free base as a 
white foamy solid (1.82 g). To a solution of the crude free base in 4 mL CH2Cl2, was added 4 mL 4M HCl 
in dioxane. The mixture was stirred for 15 min and concentrated in vacuum to afford the crude 
hydrochloride as a white solid (2.22 g). The crude HCl salt was co-evaporated once with 10 mL i-PrOH 
and then recrystallized from i-PrOH/H2O (15 mL/0.46 mL, water was added at reflux). Upon cooling, the 
desired (S,S)-diastereomer crystallized out. The crystals were filtered, washed with cold mother liquor and 
5 mL cold i-PrOH to afford 1·HCl as a white solid (427 mg, 19%). A second recrystallization gave another 
178 mg (8%). IR (neat): 2962, 2940, 2923, 2875, 2862, 2461, 1644, 1590, 1408, 1302, 1157, 972, 816, 768 
cm-1. 1H NMR (300 MHz, DMSO-d6) δ 10.39 (s, 1H), 7.70 (dd, J = 6.9, 1.9, 1H), 7.34 – 7.20 (m, 2H), 4.76 
(pseudo t, 1H), 3.77 (dd, J = 11.7, 4.7, 1H), 3.65 (br t, J = 11.7, 1H), 3.47 (dd, J = 13.3, 7.5, 2H), 3.29 – 
3.15 (m, 4H), 3.08 – 2.94 (m, 1H), 2.90 – 2.67 (m, 2H), 2.24 – 2.16 (m, 1H), 2.12 – 1.60 (m, 7H), 1.37 – 
1.21 (m, 1H). HRMS (ESI+) calcd for C19H25N2O [M-HCl+H]
+ 297.1961, found 297.1967. 
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(S)-2-((1R,3S,4R)-Quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one 
(palonosetron free base, 1). Palonosetron hydrochloride 1·HCl (196 mg, 0.59 mmol) was partitioned 
between 15 mL sat. aq. NaHCO3 solution and 30 mL EtOAc. The water phase was extracted with EtOAc 
(4 x 15 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuum to 
afford 1 as a foamy sticky solid (168 mg, 96%). 1H NMR (300 MHz, DMSO-d6) δ 7.67 (dd, J = 5.8, 3.1, 
1H), 7.29 – 7.21 (m, 2H), 4.66 – 4.56 (pseudo t, 1H), 3.78 (dd, J = 12.0, 4.7, 1H), 3.25 – 3.04 (m, 2H), 3.02 
– 2.84 (m, 3H), 2.83 – 2.67 (m, 5H), 2.11 –1.94 (m, 2H), 1.84 – 1.76 (m, 1H), 1.75 – 1.54 (m, 4H), 1.46 – 
1.35 (m, 1H), 1.32 –1.24 (m, 1H). 
(S)-8-Iodo-2-((1R,3S,4R)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-
one (13). To a solution of 1 (63 mg, 0.21 mmol) in trifluoromethanesulfonic acid (0.13 mL, 1.47 mmol), 
was added N-iodosuccinimide (287 mg, 1.28 mmol) in portions of 57 mg over a time period of 27 h. After 
stirring the reaction mixture for a total of 29 h, the reaction was quenched by addition of 10 mL 2M NaOH. 
The water phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuum to afford a brownish solid (71 mg). The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH/NH4OH (25% in H2O) 9:1:0.05) to give 
iodide 13 as a yellowish solid (37 mg, 41%). IR (neat): 2925, 2862, 1633, 1575, 1429, 1316, 1277, 1170, 
1033, 975, 820, 779 cm-1. 1H NMR (300 MHz, DMSO-d6) δ 7.94 (d, J = 1.6, 1H), 7.66 (d, J = 1.7, 1H), 
4.66 – 4.54 (pseudo t, 1H), 3.78 (dd, J = 12.2, 4.7, 1H), 3.22 – 3.14 (m, 2H), 3.08 – 2.87 (m, 3H), 2.85 – 
2.68 (m, 5H), 2.09 – 1.92 (m, 2H), 1.89 – 1.82 (m, 1H), 1.78 – 1.53 (m, 4H), 1.50 – 1.38 (m, 1H), 1.28 – 
1.23 (m, 1H). 13C NMR (100 MHz, DMSO-d6) δ 163.8, 139.4, 138.7, 137.9, 133.7, 133.1, 92.2, 50.3, 49.56, 
46.7, 46.2, 46.0, 33.9, 27.1, 27.0, 25.5, 24.8, 20.9, 20.7. HRMS (ESI+) calcd for C19H24IN2O [M+H]
+ 
423.0928, found 423.0919. 
(4-Methoxyphenyl)(palonosetron)iodonium ditosylate (14a). To a solution of iodide 13 (37 mg, 
0.088 mmol) in CH2Cl2/2,2,2-trifluoroethanol 1:1 (0.34 mL), was added p-TsOH·H2O (35 mg, 0.18 mmol). 
After p-TsOH·H2O was dissolved, dried mCPBA (commercial grade 77%, 23.5 mg, 0.11 mmol) was added 
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and complete consumption of starting material monitored by TLC. Anisole (11 mL, 0.10 mmol) was added 
thereafter, the reaction mixture stirred for 6 h at rt and subsequently concentrated in vacuum. The crude 
product was purified by flash chromatography on alumina (neutral), first using CH2Cl2/MeOH 10:0.9, then 
CH2Cl2/MeOH 10:1.4. Iodonium 14 was obtained as a white powder with unknown counterions (26 mg). 
This material was suspended in 0.5 mL MeCN and p-TsOH·H2O (15.2 mg, 0.08 mmol) added while stirring 
at rt. The mixture was concentrated in vacuum to afford a yellowish oil (34.5 mg). It was estimated by 1H 
NMR that the obtained oil contained 63% 14a and 37% p-TsOH by weight (21 mg of 14a, 27% yield). 
Alternatively, quantitative counterion exchange was accomplished using a RP-HPLC protocol as previously 
described.57 1H NMR (300 MHz, DMSO-d6, hydrogen signals originating from excess p-TsOH were 
omitted for clarity) δ 9.52 (s, 1H), 8.42 (d, J = 1.6, 1H), 8.20 (d, J = 9.0, 2H), 8.15 (d, J = 1.7, 1H), 7.47 (d, 
J = 8.0, 4H), 7.11 (d, J = 7.9, 4H), 7.07 (d, J = 9.2, 2H), 4.73 (pseudo t, 1H), 3.79 (s, 3H), 3.76 – 3.62 (m, 
2H), 3.54 – 3.41 (m, 2H), 3.33 – 3.18 (m, 4H), 3.14 – 3.04 (m, 1H), 2.94 – 2.82 (m, 1H), 2.80 – 2.71 (m, 
1H), 2.29 (s, 6H), 2.22 – 2.17 (m, 1H), 2.05 – 1.86 (m, 5H), 1.82 –1.62 (m, 2H), 1.39 – 1.31 (m, 1H). HRMS 
(ESI+) calcd for C26H30IN2O2+ [M-2TsO-H]
+ 529.1346, found 529.1352; calcd for C26H31IN2O2
2+ [M-
2TsO+H]2+ 265.0710, found 265.0715. 
(4-Methoxyphenyl)(palonosetron)iodonium ditrifluoroacetate (14b). This was synthesized 
following the procedure for 14a using iodide 13 (70 mg, 0.17 mmol) in CH2Cl2/2,2,2-trifluoroethanol 1:1 
(0.68 mL), p-TsOH·H2O (126 mg, 0.66 mmol),  dried mCPBA (commercial grade 77%, 81 mg, 0.36 mmol) 
and anisole (72 mL, 0.66 mmol). The crude product was dissolved in HPLC solvent C (0.1% TFA in water) 
containing little MeCN and the suspension was filtered. The obtained solution was purified by prep. RP18-
HPLC with UV detection at 254 nm, eluting first 2 min with 100% C, then using a gradient from 100% C 
to 55% D (0.1% TFA in MeCN/H2O 4:6) in 35 min, 55% D to 100% D in 10 min. The product eluted after 
25 min at 32% D. The combined fractions were lyophilized to give 14b as an off white solid (30 mg, 23%). 
1H NMR (300 MHz, CDCl3) δ 12.75 (s, 1H), 8.35 (s, 1H), 7.90 (d, J = 8.8, 3H), 6.91 (d, J = 8.9, 2H), 4.68 
(pseudo t, 1H), 3.82 (s, 3H), 3.89 – 3.75 (m, 1H), 3.68 – 3.56 (m, 3H), 3.38 – 3.21 (m, 4H), 3.13 – 3.01 (m, 
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1H), 2.95 – 2.70 (m, 2H), 2.36 (s, 1H), 2.20 – 1.88 (m, 6H), 1.79 – 1.63 (m, 1H), 1.32 (dd, J = 22.9, 11.1, 
1H). 13C NMR (75 MHz, CDCl3) δ 164.4, 162.8, 141.1, 140.2, 138.0, 137.2, 131.9, 131.5, 117.8, 114.8, 
104.4, 55.8, 50.9, 50.2, 49.2, 46.0, 45.9, 35.2, 28.2, 25.5, 25.0, 24.0, 21.4, 19.4. ESI-MS m/z 529 [M-2TFA-
H]+. 
(2,4,6-Trimethylphenyl)(palonosetron)iodonium ditetrafluoroborate (14c). This was 
synthesized following the procedure for 14a using iodide 13 (35 mg, 0.082 mmol) in CH2Cl2/2,2,2-
trifluoroethanol 1:1 (0.34 mL), p-TsOH·H2O (62 mg, 0.33 mmol), dried mCPBA (commercial grade 77%, 
22 mg, 0.10 mmol) and mesitylene (46 mL, 0.33 mmol). The crude iodonium salt was partitioned between 
2 mL water and 8 mL EtOAc. The water phase was washed with EtOAc (2 x 8 mL) and subsequently 
extracted with CH2Cl2 (3 x 8 mL). The combined CH2Cl2 layers were concentrated in vacuo to give the 
ditosylate salt as a white solid (49 mg, 67%). 1H NMR (300 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.11 (d, J = 
1.6, 1H), 7.89 (d, J = 1.5, 1H), 7.46 (d, J = 8.0, 4H), 7.23 (s, 2H), 7.11 (d, J = 8.0, 4H), 4.69 (pseudo t, 1H), 
3.81 – 3.70 (m, 1H), 3.71 – 3.57 (m, 1H), 3.51 – 3.39 (m, 2H), 3.29 – 3.17 (m, 4H), 3.13 – 3.02 (m, 1H), 
2.95 – 2.81 (m, 1H), 2.79 – 2.69 (m, 1H), 2.59 (s, 6H), 2.30 (s, 3H), 2.28 (s, 6H), 2.20 – 2.15 (m, 1H), 2.06 
– 1.85 (m, 5H), 1.80 – 1.62 (m, 2H), 1.33 – 1.26 (m, 1H). HRMS (ESI+) calcd for C28H34IN2O [M-2TsO-
H]+ 541.1710, found 541.1692. 
The iodonium ditosylate (49 mg, 0.055 mmol) was partitioned between 6 mL CH2Cl2 and 2 mL aq. 
1M NaBF4 solution. The aqueous layer was extracted with CH2Cl2 (2 x 6 mL). The combined organic layers 
were extracted with aq. 1M NaBF4 solution (8 mL). The remaining water phase was re-extracted with 
CH2Cl2 (2 x 10 mL). All organic CH2Cl2 layers were combined and concentrated in vacuo to afford 14c as 
a white solid (51 mg, quant.) Integration of tosylate and mesityl signals in the 1H NMR are consistent with 
almost complete anion exchange (92:8 BF4 
– :TsO–). 1H NMR (300 MHz, DMSO-d6) δ 9.49 (s, 1H), 8.11 
(d, J = 1.8, 1H), 7.89 (d, J = 1.7, 1H), 7.23 (s, 2H), 4.70 (pseudo t, 1H), 3.81 – 3.60 (m, 2H), 3.53 – 3.41 
(m, 2H), 3.30 – 3.18 (m, 4H), 3.11 – 3.03 (m, 1H), 2.93 – 2.83 (m, 1H), 2.78 – 2.71 (m, 1H), 2.59 (s, 6H), 
2.30 (s, 3H), 2.21 – 2.17 (m, 1H), 2.04 – 1.87 (m, 5H), 1.79 –1.63 (m, 2H), 1.33 – 1.27 (m, 1H). 
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(S)-8-Fluoro-2-((1R,3S,4R)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-
benzo[de]isoquinolin-1-one (fluoropalonosetron, 15). A suspension of anisyl iodonium salt 14a (35 mg, 
63 w%, 0.025 mmol) and CsF (11 mg, 0.072 mmol) in 1 mL MeCN (in a capped microwave vial) was 
stirred at 100 °C for 2 h. The reaction was transferred to an ultrasonic bath, sonicated for 1 h and 
subsequently stored in the freezer for 72 h. 2 mL acetonitrile was added and the reaction stirred at 100 °C 
for another 48 h. After allowing the reaction to cool down to rt, the mixture was partitioned between 5 mL 
CH2Cl2 and 2 mL 10% aq. NaHSO3 solution. 5 mL sat. aq. NaHCO3 solution was added and the water phase 
was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure to afford a yellow solid (12 mg). The yellow solid was dissolved in 
MeCN with little HPLC solvent C (0.1% TFA in water) and the suspension was filtered. The obtained 
solution was purified by prep. RP18-HPLC with UV detection at 254 nm, using a gradient of 90% C/10% 
E (0.1% TFA in MeCN/H2O 9:1) to 50% E in 30 min, 50% E to 100% E in 10 min. The product eluted after 
21 min at 38% E. The combined fractions were lyophilized to give 15 as the trifluoroacetate salt (1.5 mg, 
14%). 
Fluoropalonosetron 15 was also synthesized using a different method from mesityl iodonium salt 
14c. The reaction was set up in a glove box under nitrogen atmosphere using a microwave vial as reaction 
vessel. Iodonium salt 14c (48 mg, 0.067 mmol), copper(II)triflate (12 mg, 0.033 mmol), NaF (4 mg, 0.068 
mmol) and 18-crown-6 (7 mg, 0.026 mmol) were dissolved in 0.68 mL DMF. The microwave vial was 
capped and removed from the glove box. The reaction mixture was stirred at 60 °C for 21 h. DMF was 
removed in vacuo and 5 mL sat. aq. NaHCO3 solution was added. The water phase was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in 
vacuo to afford a yellow solid (21 mg). The yellow solid was dissolved in MeCN with little HPLC solvent 
C and the suspension was filtered. The obtained solution was purified by prep. RP18-HPLC with UV 
detection at 254 nm, using a gradient of 90% C/10% E to 50% E in 30 min, 50% E to 100% E in 10 min. 
The product eluted after 21 min at 38% E. The fractions were lyophilized to give 15 as the trifluoroacetate 
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salt (3.8 mg, 13%). 1H NMR (300 MHz, CDCl3) δ 13.75 (s, 1H), 7.55 (dd, J = 9.0, 2.6, 1H), 6.98 (dd, J = 
9.1, 2.5, 1H), 4.87 (pseudo t, 1H), 3.77 – 3.65 (m, 1H), 3.63 – 3.53 (m, 3H), 3.39 – 3.21 (m, 4H), 3.07 – 
2.92 (m, 1H), 2.88 – 2.77 (m, 2H), 2.42 – 2.33 (m, 1H), 2.19 – 1.89 (m, 6H), 1.80 – 1.73 (m, 1H), 1.39 – 
1.29 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 162.4, 138.0, 137.9, 132.7, 132.7, 130.4, 130.3, 119.7, 119.4, 
113.5, 113.2, 49.8, 49.6, 49.5, 46.0, 45.9, 34.9, 28.4, 26.3, 25.7, 24.5, 21.8, 19.9 (carbon directly bonded to 
fluorine, or carbonyl carbon not observed). 19F NMR (376 MHz, DMSO-d6) δ -118.87 (t, J = 9.1). ESI-MS 
m/z 315 [M+H]+. HRMS (ESI+) calcd for C19H24FN2O [M+H]
+ 315.1867, found 315.1855. 
Radiochemistry. 11C-radiolabeling of granisetron: [11C]CO2 was produced via the 
14N(p,α)11C 
nuclear reaction by bombardment of nitrogen gas fortified with 0.5% oxygen using a Cyclone 18/9 
cyclotron (18-MeV; IBA, Belgium). After reduction over a supported nickel catalyst to [11C]CH4 and 
subsequent gas phase iodination, [11C]CH3I was bubbled through a mixture of desmethyl granisetron 
precursor 3 (1.0-1.5 mg) and aq. KOH (30 µL, 5 M) in DMF (0.5 mL). The mixture was heated to 90 °C 
for 3 min. After dilution with 0.1% TFA in water (1.5 mL), the crude product was purified using the semi-
preparative HPLC system (product peak at ca. 10 min, Figure S3A). The collected product was diluted with 
water (10 mL), trapped on a C-18 cartridge (Waters, preconditioned with 5 mL EtOH and 10 mL water), 
washed with water (5 mL) and eluted with acidified EtOH (0.5 mL, 1% HCl). For formulation of the final 
product [11C]granisetron ([11C]2), PBS (9.5 mL, 0.15 M) was added to give an ethanol concentration of 5%. 
For quality control, an aliquot of the formulated solution was injected into the analytical HPLC system. The 
identity of the 11C-labeled product was confirmed by comparison with the retention time of its 
nonradioactive reference compound granisetron (2) and by co-injection with 2 (Figure S4). Specific activity 
of [11C]granisetron ([11C]2) was calculated by comparison of UV peak intensity with a calibration curve of 
the cold reference compound 2. 
18F-radiolabeling of fluoropalonosetron: No-carrier-added [18F]fluoride was produced via the 
18O(p,n)18F nuclear reaction by irradiation of isotopically enriched 18O-water in a fixed-energy Cyclone 
18/9 cyclotron (IBA). [18F]fluoride was trapped on a light QMA cartridge (Waters), which was 
-25- 
 
preconditioned with 0.5 M K2CO3 (5 mL) and water (5 mL). A 1 mL volume of Kryptofix K222/Cs2CO3 
solution (Kryptofix K222; 2.5 mg, Cs2CO3, 2.6 mg in MeCN (0.7 mL)/water (0.3 mL) was used for the 
elution of [18F−] from the cartridge. The solvents were evaporated at 100 °C under vacuum in the presence 
of slight inflow of nitrogen gas, and azeotropic drying was carried out twice with the addition of 0.8 mL 
acetonitrile each time, to afford dry [18F]CsF/K222 complex. A solution of the corresponding iodonium salt 
precursor 14 (1-2 mg in 0.5 mL dry DMF, 1-2 mg TEMPO) was added to the dried [18F]CsF/K222 complex, 
and the reaction mixture was heated at 140 °C for 12 min and then 8 mL water was added. The reaction 
mixture was passed through a preconditioned C-18 light cartridge, washed with 5 mL water, eluted the 
crude product with 1.5 mL acidified ethanol (0.2 M) and followed by 1.5 mL water. Purification was 
performed by semi-preparative HPLC, with [18F]fluoropalonosetron ([18F]15) eluting at about 22 min 
(Figure S3B). The collected product was diluted with water (8 mL), trapped on a C-18 cartridge (Waters, 
preconditioned with 5 mL EtOH and 10 mL water), washed with water (5 mL) and eluted with acidified 
EtOH (1.5 mL, 1% HCl). The ethanol solution was concentrated under vacuum to ca. 0.1 mL, then PBS (2 
mL, 0.15 M) was added to give an ethanol concentration of 5%. For quality control, an aliquot of the 
formulated solution was injected into the analytical HPLC system. The identity of the 18F-labeled product 
[18F]15 was confirmed by comparison with the retention time of its nonradioactive reference compound 
fluoropalonosetron 15 and by co-injection with 15 (Figure S5). Specific activity of [18F]fluoropalonosetron 
([18F]15) was calculated by comparison of UV peak intensity with a calibration curve of the cold reference 
compound 15. 
Radioligand Competition Binding. All cell culture reagents were obtained from commercial 
sources and were of the highest obtainable grade. Human 5-HT3A receptor subunit (accession number: 
P46098) cDNA was obtained from Prof. John Peters (Dundee University, UK) and cloned into pcDNA3.1 
(Invitrogen) for expression in HEK 293 cells. HEK 293 cells were maintained on 90 mm tissue culture 
plates at 37 °C and 7% CO2 in a humidified atmosphere. They were cultured in DMEM : F12 with Gluta-
MAX I media (DMEM/Nutrient Mix F12 (1:1), Invitrogen, Paisley, UK) containing 10 % fetal calf serum. 
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For radioligand binding studies, cells in 90 mm dishes were transfected using polyethyleneimine (PEI; 25 
kDa linear powder; Polysciences Inc., Eppelheim, Germany). 30 mL of PEI (1 mg/mL), 5 µg cDNA and 1 
mL DMEM were incubated for 10 min at room temperature, added drop wise to an 80 – 90 % confluent 
plate, and incubated for 2 – 3 days before harvesting. Transfected HEK 293 cells were scraped into 1 mL 
of ice-cold HEPES buffer (10 mM, pH 7.4) and frozen. After thawing, they were washed with HEPES 
buffer, re-suspended, and 50 mg incubated in 0.5 mL HEPES buffer containing the 5-HT3 receptor 
antagonist [3H]granisetron ([3H]2). For competition binding, reactions were incubated for 24 h at 4 °C with 
0.6 nM [3H]granisetron and differing concentrations of competing ligands palonosetron (1) and 
fluoropalonosetron 15. Non-specific binding was determined using 1 mM quipazine. Reactions were 
terminated by vacuum filtration using a Brandel cell harvester onto GF/B filters pre-soaked in 0.3% 
polyethyleneimine. Radioactivity was determined by scintillation counting using a Beckman BCLS6500 
(Fullerton, CA, USA). Individual competition binding experiments were analyzed by iterative curve fitting 
using the following equation in Prism v4.03: 
50log][
minmax
min
101
ICL
AA
Ay


  
where Amin is the non-specific binding, Amax is the maximum specific binding, [L] is the concentration of 
competing ligand and IC50 is the concentration of competing ligand that blocks half of the specific bound 
radioligand. For representative dose-inhibition curves see Figure S1. Values were calculated for separate 
experiments and reported as mean ± SEM. 
Determination of logD7.4 and In Vitro Stability Studies. The partition coefficient D was determined 
by the shake-flask method as previously described.68 In brief, n-octanol saturated with phosphate buffer pH 
7.4 (0.5 mL) and phosphate buffer saturated with n-octanol (0.5 mL) were mixed with either 
[11C]granisetron ([11C]2, 20 µL) or [18F]fluoropalonosetron ([18F]15, 10 μL). The samples were shaken for 
15 min and then centrifuged at 5000 g for 3 min. Radioactivity in each phase was measured in a gamma 
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counter (Wizard, PerkinElmer). LogD is expressed as the logarithm of the ratio between the radioactivity 
concentrations in the n-octanol and the phosphate buffer phase. 
The tracer stability was examined in vitro in rodent plasma (mouse and rat) and human plasma at 
time points 5, 10, 15 and 20 min. Plasma (400 µL) was incubated with 10 µL of [11C]granisetron ([11C]2) 
solution at 37 °C under shaking. At each time point, an aliquot (100 µL) of the mixture was collected and 
the reaction stopped with 100 µL ice-cooled MeCN. The samples were centrifuged (3 min, 5000 rpm) and 
the supernatant collected. Each sample was analyzed by UPLC (Figure S2) using a similar gradient as for 
HPLC. 
Animals. Animal care and experiments were conducted in accordance with Swiss Animal Welfare 
legislation and approved by the Veterinary Office of the Canton Zürich, Switzerland. Male Wistar rats at 5 
weeks of age were purchased from Charles River, Sulzfeld, Germany. Unless otherwise stated, for all in 
vivo experiments animals were anaesthetized with isoflurane in oxygen/air. 
In Vitro Autoradiography. Radiotracer binding was evaluated by in vitro autoradiography 
experiments with 20 μm thick coronal brain cryo-sections of a wild-type mouse (C57BL/6, male) and a rat 
(Wistar, male) mounted on glass slides (SuperFrostTM Plus, Thermo Scientific, Braunschweig, Germany). 
Slices were allowed to equilibrate on ice for 10 min before pre-incubated in HEPES buffer (30 mM HEPES, 
0.5 mM MgCl2, 110 mM NaCl, 5 mM KCl, 3 mM CaCl2, pH 7.4) supplemented with 0.1% BSA for 10 min 
at 4°C. Slices were incubated with either 0.6 nM [11C]granisetron ([11C]2) or 0.4 nM 
[18F]fluoropalonosetron ([18F]15) in HEPES/0.1% BSA for 15 min or 30 min, respectively, in a humidified 
chamber at room temperature. For blocking conditions, 1 μM cold palonosetron (1) or 1 μM cold quinoline-
4-carboxylate 6 was added to the radiotracer solution. The slices were washed for 4 min in HEPES/0.1% 
BSA buffer, twice for 3 min in HEPES buffer and twice for 5 s in distilled water at 4 °C. The air-dried 
slides were exposed to a BAS-MS 2025 phosphor imaging plate (Fuji Film, Dielsdorf, Switzerland) for 15 
min, scanned in a BAS-5000 bio-imaging reader (Fuji Film, Dielsdorf, Switzerland) and analyzed with the 
AIDA 4.5 software (Raytest, Sprockhövel, Germany). For histological characterization of the brain 
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morphology hematoxylin and eosin (HE) (Sigma, St. Louis, MO, USA) staining was applied according to 
standard protocols. All sections were covered using Eukitt mounting medium (Sigma) and digitized in a 
slide scanner (Pannoramic 250, Sysmex, Horgen, Switzerland). Specific brain regions were identified 
according to the anatomical atlas and HE staining.64 
In Vivo PET Imaging and Blocking Studies. PET scans were performed with a calibrated VISTA 
eXplore small animal PET/CT scanner (Sedecal, Madrid, Spain). Respiratory rate and temperature were 
controlled as described previously.69 In total, 8 Wistar rats (226 - 360 g) were scanned: three brain scans 
with [11C]granisetron ([11C]2) under baseline and one brain scan under blocking conditions, one body 
[11C]granisetron scan, one brain scan with [18F]fluoropalonosetron ([18F]15) under baseline and one under 
blocking conditions as well as one body [18F]fluoropalonosetron scan. Rats were intravenously injected into 
the tail vein with 46-53 MBq (brain scan) and 17 MBq (body scan) [11C]granisetron ([11C]2) or 30 - 38 
MBq (brain scan) and 17 MBq (body scan) [18F]fluoropalonosetron ([18F]15). Radiotracer injection and 
dynamic PET acquisition (list mode) were started simultaneously and PET scan duration was 60 min. 
Blocking scans were performed by injecting 100 μL cold palonosetron (1, 100 μg/kg) intravenously shortly 
before radiotracer application. At the end of each scan, a CT was recorded for anatomical orientation. PET 
data were reconstructed in user-defined time frames (2D-OSEM) applying random and scatter corrections. 
Time-activity curves (TACs) of brain regions were generated with the implemented rat brain region of 
interest (ROI) template supplied by PMOD biomedical imaging software (3.6, PMOD Technologies Ltd., 
Zürich, Switzerland). Standardized uptake values (SUV) were calculated as tissue activities (Bq/cm3), 
normalized to the injected dose per body weight (Bq/g). 
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